FDA OKs VIVUS QSYMIA® for Treatment of Obesity in Ages 12-17

 VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adolescents (12-17 years old) with an initial body-mass index (BMI) in the 95th percentile or greater standardized for age and sex. According to the CDC, approximately 22% of children aged 12-19 years in the United States — about 14 million individuals — have obesity.

The results of the QSYMIA Phase 3 trial in adolescent patients taking the top-dose demonstrated that more than 44% of patients lost at least 15% of their body weight and more than 30% of patients lost at least 20% of their body weight.

https://www.biospace.com/article/releases/fda-approves-qsymia-for-the-treatment-of-obesity-in-adolescents-ages-12-17/